|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | RTI Biologics |
|---|---|
| Information provided by: | RTI Biologics |
| ClinicalTrials.gov Identifier: | NCT00255970 |
Purpose
The purpose of this research study was to determine whether treatment with the bone grafting material Regenafil was as effective as the standard treatment using demineralized freeze dried bone allograft (DFDBA). Regenafil is demineralized freeze dried bone in a special gel form.
| Condition | Intervention | Phase |
|---|---|---|
|
Periodontal Diseases |
Other: DFDBA Device: Regenafil |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Regenerative Therapy for Vertical Defects Comparing Demineralized Freeze Dried Bone Allograft (DFDBA) and Regenafil |
Scores:
0 Normal gingiva
0- No plaque
The variable measured the presence of bleeding when the osseus defect was probed. The presence and character of gingival bleeding will be determined by gently probing to the base of the pockets.
0 - No bleeding.
1 - Bleeding when probing.
Tooth mobility was recorded using Miller's Index:
| Enrollment: | 40 |
| Study Start Date: | January 2006 |
| Study Completion Date: | November 2007 |
| Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Regenafil graft
Regenafil
|
Device: Regenafil
Demineralized Freeze Dried Bone in a porcine gel carrier
Other Names:
|
|
Active Comparator: DFDBA
Demineralized Freeze Dried Bone Allograft
|
Other: DFDBA
Demineralized Freeze Dried Allograft bone
Other Name: Demineralized Bone Matrix
Device: Regenafil
Demineralized Freeze Dried Bone in a porcine gel carrier
Other Names:
|
To compare the regenerative effects of a demineralized freeze dried bone allograft (DFDBA) particulate in a biologic thermoplastic carrier (Regenafil) to the standard of care. To compare the regenerative effects of a demineralized freeze dried bone allograft (DFDBA) particulate in the treatment of intraosseous vertical defects following six months of healing. This was accomplished by evaluating clinical parameters including probing depth, attachment level and bleeding upon probing, using attachment level as the primary outcome variable.
Treatment of the vertical osseous defect is a challenging problem in periodontics. There are many treatment options including:
Choice of treatment may depend on the defect depth and configuration. A shallow, narrow 3 wall defect may respond well to open flap debridement while a deep 2 wall defect may need regenerative therapy such as an osseous graft, a membrane or combined membrane and graft treatment. Studies of vertical defect therapy with defects about 4 mm or greater show that similar percent defect fill results are obtained with regenerative therapies. Open flap debridement produces substantially less percent defect fill.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Have a known allergy to any of the materials that will be used in the study:
Contacts and Locations| United States, Indiana | |
| Indiana University School of Dentistry | |
| Indianapolis, Indiana, United States, 46202 | |
| United States, Kentucky | |
| University of Louisville School of Dentistry | |
| Louisville, Kentucky, United States, 40202 | |
| Principal Investigator: | Henry Greenwell, DMD | University of Louisville |
| Principal Investigator: | Steven Blanchard, DDS | Indiana University School of Dentistry |
More Information
| Responsible Party: | Sponsor, Regeneration Technologies, Inc |
| ClinicalTrials.gov Identifier: | NCT00255970 History of Changes |
| Other Study ID Numbers: | RegenF052005 |
| Study First Received: | November 16, 2005 |
| Results First Received: | June 9, 2009 |
| Last Updated: | August 8, 2011 |
| Health Authority: | United States: Food and Drug Administration |
|
Periodontal Treatment of Intraosseous Vertical Defects |
|
Periodontal Diseases Mouth Diseases Stomatognathic Diseases |